SCR 8 Hawaii Senate · 2025 Regular Session

REQUESTING THE AUDITOR TO ASSESS BOTH THE SOCIAL AND FINANCIAL EFFECTS OF PROPOSED MANDATED HEALTH INSURANCE COVERAGE FOR A PERCENTAGE OF THE COSTS OF INTRAVENOUS KETAMINE THERAPY TO TREAT DEPRESSION.

SCR 8 is a procedural resolution requesting the Hawaii Auditor to study the social and financial impacts of mandating insurance coverage for intravenous ketamine therapy for depression. It specifically asks the Auditor to assess coverage for "a percentage of the costs" under S.B. 967 (a separate bill proposing this mandate), focusing on both patient access and financial implications. The resolution requires the Auditor to submit findings to the Legislature by January 2026, before the next legislative session. This study is a legal prerequisite under Hawaii law (HRS § 23-51) before the Legislature can consider enacting the insurance mandate. The resolution itself does not change coverage rules but directs an analysis of potential effects.

Bill status passed 4 of 5 stages cleared

Introduction

Jan 2025

Committee Review

Apr 2025

Senate Passage

Mar 2025

House Passage

Apr 2025

Governor

Introduced Jan 30, 2025 Last action Apr 14, 2025

Maddy AI version diff · 1 comparison

What changed between versions

SCR8 → SCR8_SD1 · 5 edits

MODERATE

The bill was updated from a draft version to a formal Senate Concurrent Resolution (SCR 8 SD1). The main substantive change is that the specific Senate Bill being reviewed was identified as S.B. No. 967, and the resolution now requests the Auditor to assess various percentages of coverage costs rather than a single unspecified percentage. Several formatting and metadata elements were added or removed during the conversion from a document template to a formal legislative text.

Scope change

The resolution now specifically references S.B. No. 967 as the bill requiring insurance coverage for intravenous ketamine therapy, and expands the Auditor's analysis to cover various percentages of coverage costs for qualifying patients.

REQUIREMENT

The resolution now specifically identifies S.B. No. 967 as the bill requiring insurance coverage for intravenous ketamine therapy, replacing a placeholder reference to 'Senate Bill No.'

The Auditor's analysis scope was expanded to assess various percentages of coverage costs for qualifying patients, rather than a single unspecified percentage

TECHNICAL

Added metadata fields including document version numbers, timestamps, and template revision information

Removed placeholder text and document metadata that was part of the original draft template

Added a report title line at the end specifying the subject matter of the Auditor's report

Floor votes · House Apr 14, 2025

How they voted

This bill passed the Senate. No roll call record of that vote is available.

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Apr 14, 2025

Committee

Report adopted; referred to the committee(s) on FIN with none voting aye with reservations; none voting no (0) and none excused (0).

lower

Apr 14, 2025

Committee

Reported from HLT (Stand. Com. Rep. No. 2071), recommending referral to FIN.

lower

Apr 14, 2025

House · Passed

House Vote: pass (50-0)

house

Apr 11, 2025

Lower · Passed

The committee on HLT recommend that the measure be PASSED, UNAMENDED. The votes were as follows: 7 Ayes: Representative(s) Takayama, Keohokapu-Lee Loy, Amato, Chun, Marten, Olds, Alcos; Ayes with reservations: none; Noes: none; and 2 Excused: Representative(s) Takenouchi, Garcia.

lower

Apr 4, 2025

Committee

Referred to HLT, FIN, referral sheet 28

lower

Mar 31, 2025

Introduced

Received from Senate (Sen. Com. No. 415) in amended form (SD 1).

lower

Mar 31, 2025

Upper · Passed

Resolution Adopted as amended (SD1). Aye(s) with reservations: Senator(s) McKelvey. Noes, 0 (none). Transmitted to House.

upper

Mar 28, 2025

Committee

Waived referral to WAM.

upper

Mar 24, 2025

Committee

Report adopted, as amended (SD 1) and referred to WAM.

upper

Mar 24, 2025

Committee

Reported from HHS (Stand. Com. Rep. No. 1360), as amended (SD 1), with recommendation of referral to WAM.

upper

Mar 24, 2025

Upper · Passed

The committee(s) on HHS recommend(s) that the measure be PASSED, WITH AMENDMENTS. The votes in HHS were as follows: 4 Aye(s): Senator(s) San Buenaventura, Aquino, Hashimoto, Keohokalole; Aye(s) with reservations: none ; 0 No(es): none; and 1 Excused: Senator(s) Fevella.

upper

Mar 20, 2025

Upper · Passed

The committee(s) on HHS has scheduled a public hearing on 03-24-25 1:05PM; Conference Room 225 & Videoconference.

upper

Feb 3, 2025

Committee

Referred to HHS, WAM.

upper

Jan 30, 2025

Introduced

Offered.

upper

1 primary · 0 co-sponsors